A Phase 2 interventional study of Alemtuzumab and Total Body Irradiation in Sickle Cell Disease, Stem Cell Transplant Complications and Red Blood Cell Disorder, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 1 Year to 19 Years. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University of Calgary · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing alemtuzumab in Anemia, Sickle Cell — 6 open to participants now, 14 under way, none of them phase 3. Alemtuzumab · Anemia, Sickle Cell.
Among the 22 studies testing alemtuzumab in Anemia, Sickle Cell, this one is the 16th largest by planned enrollment, is one of 3 that started in 2017, is one of 11 in phase 2, reaches primary completion later than 8 of the 13 other live ones, and was the 14th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →6 of the 22 studies testing alemtuzumab in Anemia, Sickle Cell are open now, in 2 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 4–65
Paul Szabolcs · Sites in United States
Ages 5–40
Robert Nickel · Sites in United States, Canada
Ages 2–25
Paul Szabolcs · Sites in United States
Ages 2 mo–55 yrs
By country, each count listing its studies:
Alemtuzumab: first FDA approval 2001 (LEMTRADA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 1 Year to 19 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 17 · Phase 3 2
First in 1999; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 44 across the 22 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 1 study filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
3 of the studies testing alemtuzumab in Anemia, Sickle Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04018937Emory UniversityEarly Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation | 2026-11 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT05384756City of Hope Medical CenterTMLI and Alemtuzumab for Treatment of Sickle Cell Disease | 2026-12-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing alemtuzumab in Anemia, Sickle Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.
Sickle cell disease (SCD) is a debilitating chronic blood disorder with multi-system end-organ damage that leads to morbidity and early mortality. The only cure for SCD is hematopoietic stem cell transplantation (HSCT), which given the risks with unrelated HSCT, is only an option for a minority of patients who have a matched sibling donor.
In the field of HSCT, blood group ABO incompatibility between donor and recipient is not a contraindication and several studies do not show compromised outcomes. However, in the context of nonmyeloablative (NMA) conditioning and major ABO-incompatibility, when the recipient has existing antibodies to donor red blood cells, pure red cell aplasia (PRCA) may occur.
This phase II pilot study will enroll SCD patients with a matched related major ABO-incompatible donor to determine the safety and efficacy of NMA-HSCT. Biological studies will include a plan to study and monitor red cell engraftment in this population to facilitate early detection and interventional measures to prevent and treat PRCA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have sickle cell disease as defined by electropheresis, as follows:
Patients must meet standard eligibility criteria to undergo , including but not limited to one or more of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-myeloablative conditioning
Drug: Alemtuzumab · Radiation: Total Body Irradiation · Drug: Sirolimus
Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
Also known as: Campath
TBI 300 cGy on Day -2
Also known as: TBI
Sirolimus is used for GVHD prophylaxis
Incidence of pure red cell aplasia (PRCA)
Clinical definition: reticulocytopenia \< 10x109/L (\< 1%) lasting more than 60 days after HSCT, or Pathological definition: the absence of erythroid precursors in the marrow in the setting of adequate myeloid, lymphoid and megakaryocytic precursors
Time frame: 6 months from enrollment
RBC chimerism measured by peripheral blood flow cytometry
Peripheral blood for RBC chimerism on flow sorted erythroid precursor cells
Time frame: 12 months
RBC chimerism measured by bone marrow BFU-erythroid forming colonies
Bone marrow will be performed between Day +45 and +60
Time frame: 2 months
Primary graft failure
Measured by donor chimerism from peripheral blood and bone marrow
Time frame: 6 weeks
Secondary graft failure
Measured by donor chimerism in peripheral blood and bone marrow
Time frame: 24 months
Disease recurrence
Measured by peripheral blood Hb S level
Time frame: 24 months
Incidence and severity of acute GVHD
Acute GVHD grade will be accessed using modified CIBMTR criteria
Time frame: 100 days
Incidence and severity of chronic GVHD
Chronic GVHD will be accessed using the NIH consensus criteria
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2017 (actual). Primary completion is estimated for Jul 2028, 132 months after the start.
Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 132 months is above that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alemtuzumab · Sirolimus